Search
Sugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalThe antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation … [L53333] In combination with platinum-based chemotherapy, sugemalimab is a first-line treatment indicated for adult populations with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational[L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141] … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.
Tizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalInitially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons … It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.
Mixtures: MYOS -NOR F TABLETASOritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt was developed by The Medicines Company (acquired by Novartis). … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections.
Topotecan
go.drugbank.com/drugs/DB01030ApprovedInvestigationalAn antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026. … [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain.
Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamideEdotreotide gallium Ga-68
go.drugbank.com/drugs/DB15494Approved[A185852] Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.[A185852] Edotreotide gallium Ga-68 was granted FDA approval on 21 August 2019.[L8597] … [L8603] Edotreotide gallium Ga-68 is indicated for localizing somatostatin receptor positive neuroendocrine tumors by positron emission tomography.
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnCurrently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood
Meprobamate
go.drugbank.com/drugs/DB00371ApprovedIllicitMeprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). … It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines.
Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients. … [A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170]